These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23777088)

  • 1. [Update of the treatment of multiple sclerosis].
    Miyamoto K
    Nihon Rinsho; 2013 May; 71(5):817-21. PubMed ID: 23777088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod: a novel immunosuppressant for multiple sclerosis.
    Brown BA; Kantesaria PP; McDevitt LM
    Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An update on the treatment options for multiple sclerosis].
    Niino M
    Brain Nerve; 2012 Dec; 64(12):1421-6. PubMed ID: 23209069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.
    D'Amico E; Leone C; Caserta C; Patti F
    Expert Rev Neurother; 2015; 15(7):803-24. PubMed ID: 26098146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multiple sclerosis: between wish and reality].
    Kümpfel T; Hohlfeld R
    MMW Fortschr Med; 2005 May; 147 Spec No 2():83-5. PubMed ID: 15968879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging oral agents for multiple sclerosis.
    Fox EJ
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and emerging disease modifying therapies for multiple sclerosis.
    Saidha S; Eckstein C; Calabresi PA
    Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
    Széplaki G; Merkely B
    Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapies in multiple sclerosis.
    Farrell R; Heaney D; Giovannoni G
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):797-816. PubMed ID: 16262563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
    Hecht B
    Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cladribine as a therapeutic option in multiple sclerosis.
    Warnke C; Leussink VI; Goebels N; Aktas O; Boyko A; Kieseier BC; Hartung HP
    Clin Immunol; 2012 Jan; 142(1):68-75. PubMed ID: 21733757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded clinical trials of treatments for multiple sclerosis. The Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis of The National Multiple Sclerosis Society.
    Whitaker JN
    Ann Neurol; 1993 Dec; 34(6):755-6. PubMed ID: 8250523
    [No Abstract]   [Full Text] [Related]  

  • 13. [Mitoxantrone for the treatment of patients with multiple sclerosis].
    Komori M; Kondo T; Tanaka M
    Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded clinical trials of treatments for multiple sclerosis: copolymer 1 (COP-1) treatment investigational new drug (IND) program.
    Stark Y
    Ann Neurol; 1994 Jul; 36(1):114-5. PubMed ID: 8024251
    [No Abstract]   [Full Text] [Related]  

  • 15. Psoriatic arthritis - treatment update.
    Mease PJ
    Bull NYU Hosp Jt Dis; 2011; 69(3):243-9. PubMed ID: 22035437
    [No Abstract]   [Full Text] [Related]  

  • 16. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
    Strader CR; Pearce CJ; Oberlies NH
    J Nat Prod; 2011 Apr; 74(4):900-7. PubMed ID: 21456524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Principles of a new treatment algorithm in multiple sclerosis.
    Hartung HP; Montalban X; Sorensen PS; Vermersch P; Olsson T
    Expert Rev Neurother; 2011 Mar; 11(3):351-62. PubMed ID: 21375441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon.
    Marta M; Giovannoni G
    CNS Neurol Disord Drug Targets; 2012 Aug; 11(5):610-23. PubMed ID: 22583439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.